CMS coverage decision for type 2 non-insulin Medicare population expected before end-2026, with coverage taking effect mid-2027.
Prime Therapeutics coverage for all people with diabetes starts summer 2026, supporting more than 7 million commercial type 2 non-insulin covered lives by year-end.
DexCom expects to convert nearly 50% of its U.S. customer base to G7 15-day by end-2026.
Ireland manufacturing facility ramp accelerates into Q3 2026, with hiring and training before production lines are turned on later in the year.
DexCom Flex, a 15-day sensor for type 2 basal and non-insulin markets, will continue rolling out in select international geographies as reimbursement builds.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for DexCom, Inc. and 4,900+ companies.